Noguchi S, Tahara H, Miyauchi K, Koyama H
Department of Surgery, Center for Adult Diseases, Osaka, Japan.
Oncology. 1989;46(4):273-6. doi: 10.1159/000226730.
The influence of 1 alpha,25-dihydroxyvitamin D3 (1,25-(OH)2D3) on the development and steroid hormone receptor contents of 7,12-dimethylbenzanthracene (DMBA)-induced rat mammary tumors was evaluated. Neither the incidence nor the size of the tumors was affected by the 1,25-(OH)2D3 treatment (1 or 2 micrograms twice a week for 16 weeks) but estrogen and progesterone receptor contents of the tumors were significantly lower in 1,25-(OH)2D3-treated groups as compared to the control group. These results demonstrate that 1,25-(OH)2D3 at doses producing mild hypercalcemia does not affect the development of DMBA-induced rat mammary tumors but decreases the estrogen and progesterone receptor contents of the tumors.
评估了1α,25 - 二羟基维生素D3（1,25-(OH)2D3）对7,12 - 二甲基苯并蒽（DMBA）诱导的大鼠乳腺肿瘤的发生发展及类固醇激素受体含量的影响。1,25-(OH)2D3处理（每周两次，每次1或2微克，共16周）对肿瘤的发生率和大小均无影响，但与对照组相比，1,25-(OH)2D3处理组肿瘤的雌激素和孕激素受体含量显著降低。这些结果表明，产生轻度高钙血症剂量的1,25-(OH)2D3不影响DMBA诱导的大鼠乳腺肿瘤的发生发展，但会降低肿瘤的雌激素和孕激素受体含量。
